To address the issue of GEM‐resistant pancreatic cancer, we designed a novel nanocage, GEM‐DVDMS@MOFs@COF‐NRP2 (GDMCN2), which specifically targets human GEM‐resistant cells (PANC‐1/GEM) via pancreatic cancer‐specific targeting. Here, NRP2 is linked to pancreatic neoplasm.